FDA launches “Bad Ad Program” to detect misleading drug ads

FDA Launches Next Stage of "Bad Ad Program" to Detect Misleading Drug Ads. The program is designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading. For more information visit www.fda.gov/badad.

New Next-generation OmniPod® Approved by FDA. The new OmniPod insulin pump is more than one-third smaller and one-quarter lighter than the original model, while maintaining the same 200-unit insulin reservoir capacity.